Skip to main content

Table 2 Ongoing clinical trials of immune checkpoint blockades in SCLC

From: Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer

Study

Stage

Ph

Pts.

Design

Primary end point

NCT number

Primary completion

First-line

 KEYNOTE-604

ED

III

453

Pembro+EP v Placebo+EP

PFS, OS

NCT03066778

December 2019

 REACTION

ED

II

118

Pembro+EP v EP

6-month PFS

NCT02580994

August 2020

  NA

LD/ED

I

80

Pembro+EP ± RT

MTD

NCT02402920

July 31, 2023

  NA

LD

II / III

506

Atezo+EP+RT v EP+RT

PFS, OS

NCT03811002

May 2024

 CASPIAN

ED

III

988

Durva±Treme+EP v EP

PFS, OS

NCT030s43872

September 2019

 CLOVER

LDb

I

300

Durva±Treme+EP

DLT; AE

NCT03509012

April 2022

  PAVE

ED

II

55

Avelumab+EP

1- year PFS

NCT03568097

November 2020

Second-line and beyond

 BLOLUMA

LD/EDa

II

106

Nivo+Ipi

ORR

NCT03083691

March 2019

 MCC-19163

LD/ED

II

41

Nivo+Ipi+Ad.p53-DC vaccine

DCR

NCT03406715

April 2020

 CA209-9YT

ED

II

40

Nivo+Ipi

Teff/Treg

NCT03670056

September 2020

  NA

ED

II

29

Nivo+Gemcitabine

ORR

NCT03662074

September 2020

  AFT-17

LD/ED

II

98

Pembro v Topotecan

PFS

NCT02963090

May 2019

 KEYNOTE PN758

ED

I/ II

84

Pembro+Pegzilarginase

AE, ORR

NCT03371979

December 2020

  NA

LD/ED

II

80

Pembro+EP±RT

PD-L1

NCT02934503

October 2019

 ML39728

LD/ED

II

35

Atezo

ORR

NCT03262454

December 2019

 Winship3112-15

LD/ED

II

28

Durva±Treme+RT v RT

PFS, ORR

NCT02701400

January 2020

 PASSION

ED

II

135

SHR-1210+Apatinib

AE, ORR

NCT03417895

March 2019

Maintenance

 STIMULI

LD

II

260

Nivo+Ipi v Obsesrvation

PFS, OS

NCT02046733

October 2019

 CA209-840

ED

I/ II

21

Nivo+Ipi+RT

PFS

NCT03043599

April 2021

 ACHILES

LD

II

212

Atezo v Observation

2-year OS

NCT03540420

December 2023

  NA

LD

II

51

Durva+EP+RT

PFS

NCT03585998

June 2021

 ADRIATIC

LD

III

600

Durva±Treme v Placebo

PFS, OS

NCT03703297

June 2021

  1. Abbreviations: ED extensive-stage, LD limited-stage, a including NSCLC, b including 3 other solid tumors, ORR objective response rate, PFS progression-free survival, OS overall survival, AE adverse event, Nivo nivolumab, Ipi ipilimumab, RT radiotherapy, Pem pembrolizumab, EP etoposide plus platinum, MTD maximum tolerated dose, Atezo atezolizumab, Durva durvalumab, Treme tremelimumab, DLT dose-limiting toxicities, NA not available